Pappas Capital is a global venture capital and commercial development firm based in Research Triangle Park, North Carolina. For more than three decades, the firm has identified and supported companies tackling unmet needs in healthcare, biotechnology and agriculture. Its global reach includes North America, Canada and Asia, partnering with entrepreneurs and research institutions to accelerate commercial development. Through three core business lines—Pappas Ventures for life science financing, Specialized Fund Management for customized investment vehicles and Translational Medicine partnerships with universities—Pappas Capital nurtures innovation from early concept through market launch.
The firm focuses on early-stage companies developing biopharmaceuticals, gene therapies, medical devices and agricultural technologies. Pappas Capital has backed more than 100 companies across the United States, Canada and Asia, guiding products that treat conditions such as melanoma, ovarian cancer and hemophilia. Many portfolio companies have achieved regulatory milestones and generated meaningful revenue, treating tens of thousands of patients worldwide. Its professional team offers strategic insight, operational support and access to a broad network of industry associations to help portfolio companies grow and deliver patient and environmental impact. The firm collaborates with groups like the National Venture Capital Association and the Biotechnology Innovation Organization to further support portfolio growth.
In a recent expansion beyond life sciences and AgTech, Pappas Capital invested in VFlowTech, a cleantech company developing vanadium-based redox flow batteries for long-duration energy storage. Participating in a $10 million Series A round, the firm supports VFlowTech’s effort to scale modular, sustainable energy systems for grid support, electric vehicle charging and off-grid applications. This investment in energy storage marks a notable expansion outside the firm’s traditional focus and underscores its ability to support emerging technologies that address global challenges. These efforts reflect Pappas Capital’s commitment to addressing critical healthcare and environmental needs through targeted investments.
